Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells
Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost the sensitivity of leukemia to antitumor NK cell activity. DCAF15 deletion upregulated the lymphocyte costimulatory molecule CD80 in chronic myelogenous leukemia (CML) cells, resulting in amplified cell death when cocultured with NK cells. Reduced DCAF15 was associated with increased

Read the full 732 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE